Abbvie ((ABBV)), Genmab (Otc) ((GMAB)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie and Genmab are conducting a global Phase 2 trial to evaluate the efficacy and safety of epcoritamab, both as a standalone treatment and in combination with lenalidomide, for elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL) who cannot tolerate anthracycline therapy. This study, titled ‘Efficacy and Safety of Epcoritamab Monotherapy and in Combination With Lenalidomide as First-line Therapy for Anthracycline-ineligible Diffuse Large B-Cell Lymphoma Patients,’ aims to provide new treatment options for this patient group.
The interventions being tested include subcutaneous epcoritamab injections and oral lenalidomide capsules. Epcoritamab is an antibody designed to target cancer cells, while lenalidomide is a drug that modulates the immune system.
The study is designed as an open-label, randomized, multicenter trial with a parallel intervention model and no masking. Its primary purpose is treatment, with participants randomly assigned to receive either epcoritamab alone or in combination with lenalidomide.
Key dates for the study include a start date of March 6, 2023, and a last update on August 4, 2025. These dates are crucial for tracking the study’s progress and potential impact on the market.
This update could influence AbbVie and Genmab’s stock performance by potentially enhancing their treatment portfolios and attracting investor interest. The study’s progress is particularly significant in the competitive oncology market, where new therapies are in high demand.
The study is ongoing, with further details available on the ClinicalTrials portal.